(S)-2-氨基-2-乙基己酸 | 6300-78-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-氨基-2-乙基己酸
• 英文名称: 2-Amino-2-ethyl-hexanoic acid
• 英文别名: 2-azaniumyl-2-ethylhexanoate
• CAS: 6300-78-3
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: QUDXVGQYPUXXER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  (S)-2-氨基-2-乙基己酸 在 porcine liver esterase 、 硫酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 phosphate buffer 、 乙腈 为溶剂， 反应 25.5h， 生成 ethyl trifluoroacetyl-(S)-2-butyl-2-ethylglycyl-(S)-2-butyl-2-ethylglycinate
  参考文献：
  名称：

  The First Fully Planar C ₅ ‐Conformation of Homooligopeptides Prepared from a Chiral α ‐Ethylated α , α ‐Disubstituted Amino Acid: ( S )‐Butylethylglycine (=(2 S )‐2‐Amino‐2‐ethylhexanoic Acid)

  摘要：

  An optically active alpha -ethylated alpha,alpha -disubstituted amino acid, (S)-butylethylglycine (= (2S)-2-amino-2-ethylhexanoic acid; (S)-Beg; (S)-2),was prepared starring from butyl ethyl ketone (1) by the Strecker method and enzymatic kinetic resolution of the racemic amino acid. Homooligopeptides containing (S)-Beg (up to hexapeptide) were synthesized by conventional solution methods. An ethyl cater was used for the protection at the C-terminus, and a trifluoroacetyl group was used for the N-terminus of the peptides. Thr structures of tri- and tetrapeptides 5 and 6 in the solid state were solved by X-ray crystallographic analysis, and were shown to have a bent planar C-conformation (tripeptide) and a fully planar C-5-conformation (tetrapeptide) (see Figs. I and 2, resp.). The IR and H-1-NMR spectra of hexapeptide 8 revealed that the dominant conformation in CDCl3, solution was also a fully planar C-5-conformation, These results show for the first time that the preferred conformation of homopeptides containing a chiral alpha -ethylated alpha,alpha -disubstituted amino acid is a planar C-5-conformation.

  DOI：

  10.1002/1522-2675(20001004)83:10<2823::aid-hlca2823>3.0.co;2-#
• 作为产物：
  描述：

  3-庚酮 在 盐酸 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 72.0h， 生成 (S)-2-氨基-2-乙基己酸
  参考文献：
  名称：

  The First Fully Planar C ₅ ‐Conformation of Homooligopeptides Prepared from a Chiral α ‐Ethylated α , α ‐Disubstituted Amino Acid: ( S )‐Butylethylglycine (=(2 S )‐2‐Amino‐2‐ethylhexanoic Acid)

  摘要：

  An optically active alpha -ethylated alpha,alpha -disubstituted amino acid, (S)-butylethylglycine (= (2S)-2-amino-2-ethylhexanoic acid; (S)-Beg; (S)-2),was prepared starring from butyl ethyl ketone (1) by the Strecker method and enzymatic kinetic resolution of the racemic amino acid. Homooligopeptides containing (S)-Beg (up to hexapeptide) were synthesized by conventional solution methods. An ethyl cater was used for the protection at the C-terminus, and a trifluoroacetyl group was used for the N-terminus of the peptides. Thr structures of tri- and tetrapeptides 5 and 6 in the solid state were solved by X-ray crystallographic analysis, and were shown to have a bent planar C-conformation (tripeptide) and a fully planar C-5-conformation (tetrapeptide) (see Figs. I and 2, resp.). The IR and H-1-NMR spectra of hexapeptide 8 revealed that the dominant conformation in CDCl3, solution was also a fully planar C-5-conformation, These results show for the first time that the preferred conformation of homopeptides containing a chiral alpha -ethylated alpha,alpha -disubstituted amino acid is a planar C-5-conformation.

  DOI：

  10.1002/1522-2675(20001004)83:10<2823::aid-hlca2823>3.0.co;2-#

文献信息

• Hypolipidemic 1,4-benzothiazepine derivative
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP1203769A1

  公开（公告）日：2002-05-08

  The invention is concerned with a novel hypolipidemic compound, which is of (3R,5R)-3-Butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-5-phenyl-1,4-benzothiazepin-8-ol 1,1-dioxide; or a salt, solvate, or physiologically functional derivative thereof, with processes for its preparation, pharmaceutical compositions containing it and with its use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as athersclerosis.

  这项发明涉及一种新型降脂化合物，即(3R,5R)-3-丁基-3-乙基-2,3,4,5-四氢-7-甲氧基-5-苯基-1,4-苯并噻吩-8-醇-1,1-二氧化物；或其盐、溶剂合物或生理功能衍生物，以及其制备方法、含有它的药物组合物，以及在医学中的应用，特别是在预防和治疗高脂血症等高脂血症状况中的使用。
• [EN] ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS CYCLIQUES ACYLAMINO-SUBSTITUÉS DE L'ACIDE CARBOXYLIQUE ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2011053948A1

  公开（公告）日：2011-05-05

  The present invention relates to compounds of the formula (I) wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

  本发明涉及式(I)的化合物，其中A、Y、Z、R20至R22和R50具有索引中指示的含义，这些化合物是有价值的药用活性化合物。具体来说，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体被溶血磷脂酸（LPA）激活，也被称为LPA1受体，对于治疗动脉粥样硬化、心肌梗死和心力衰竭等疾病是有用的。此外，本发明还涉及制备式(I)化合物的方法、它们的用途以及包含它们的药物组合物。
• [EN] HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES<br/>[FR] 1,4-BENZOTHIAZEPINE-1,1-DIOXYDES A ACTION HYPOLIPIDEMIQUE
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：WO1996005188A1

  公开（公告）日：1996-02-22

  (EN) The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermediates for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as atherosclerosis.(FR) Cette invention se rapporte à de nouveaux composés hypolipidémiques, représentés par la formule (I), à des procédés et à de nouveaux intermédiaires servant à leur préparation, à des compositions pharmaceutiques qui les contiennent et à leur utilisation en médecine, particulièrement pour la prophylaxie et le traitement d'états hyperlipidémiques, tels que l'athérosclérose.

  该发明涉及化学式（I）的新型降脂化合物，以及用于制备它们的新型中间体和工艺，含有它们的药物组合物，以及它们在医学上的使用，特别是在预防和治疗高脂血症状况，如动脉粥样硬化。
• In vivo incorporation of unnatural amino acids
  申请人：Schultz Peter

  公开号：US20090068717A1

  公开（公告）日：2009-03-12

  The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids.

  本发明提供了在体内合成非天然氨基酸的方法和组合物。同时还提供了包含非天然氨基酸蛋白质的组合物。
• Preliminary biological studies of several aliphatic amino acid analogs
  作者：C. J. Abshire、G. Planet

  DOI：10.1021/jm00273a004

  日期：1972.3